Skip to content

Optimal rhCG(Ovidrel®) Dose in Poor Responder During IVF and ICSI Cycles

Optimal rhCG(Ovidrel®) Dose for Final Oocyte Maturation Triggering in Poor Responder During IVF and ICSI Cycles

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01406600
Enrollment
70
Registered
2011-08-01
Start date
2011-09-30
Completion date
2013-12-31
Last updated
2013-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

in Vitro Fertilization, Poor Responder

Keywords

recombinant hCG, poor responder, oocyte maturity

Brief summary

Choriogonadotropin alfa (Ovidrel®) is a recombinant hCG (rhCG) preparation derived from genetically engineered Chinese hamster ovary cells, which is widely used for final oocyte maturation triggering in assisted reproductive technology (ART).Recombinant hCG has been investigated about its safety and efficacy comparing with urinary hCG, but still the optimal dose of rhCG is questionable. From former studies, there only have been proven that high dose of hCG can make ovarian hyperstimulation syndrome (OHSS) in usual condition. On the other hand, we hypothesize that high dose of hCG may improve oocyte maturity in poor responders who cannot easily provoke OHSS. Hence, this study will assess the comparative efficacy and safety of 250mcg and 500mcg of rhCG in ART treatment cycle.

Detailed description

Randomized prospective clinical study that compare the two doses of rhCG (250mcg vs. 500mcg).

Interventions

DRUGrecombinant hCG (Ovidrel®)

Recombinant hCG (Ovidrel®)will be administrated for final oocyte maturation triggering in poor responders with different two doses (250mcg vs. 500mcg). Usually rhCG is administrated after 24\ 48 hours from optimal ovarian stimulation status.

Sponsors

Seoul National University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
21 Years to 44 Years
Healthy volunteers
No

Inclusion criteria

* poor response in prior IVF cycle (≤ 4 oocyte retrieved) * women's age ≥ 40 years * FSH ≥ 10mIU/mL or AMH ≤ 1.1ng/mL * Antral follicle count \<6

Exclusion criteria

* patient without informed consent

Design outcomes

Primary

MeasureTime frameDescription
oocyte maturityUp to the ovum pick up day. At the point of ovum pick-up, we can count how many mature or immature oocytes were retrived. Therefore, in one hour after ovum pick-up, outcome measurement will be possible.After administration of different doses of rhCG, oocyte maturity will be assessed on ovum pick up day. Oocytes will be classified into GV, MI, and MII.

Secondary

MeasureTime frame
clinical pregnancy rateAfter confirming fetal heart beat via transvaginal ultrasound. Usually 2 to 4 weeks after ovum pick-up day.

Countries

South Korea

Contacts

Primary ContactKyung Eui Park, M.D.
kepark.md@gmail.com+82-2-2072-3529

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026